drugset / Trial / NCT02611167
Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, feasibility, and efficacy of intravenous allogeneic bone marrow-derived mesenchymal stem cell (MSC) therapy for idiopathic Parkinson's disease (iPD).
Timeline
- Start
- 2017-11-01
- Primary completion
- 2019-09-18
- Completion
- 2019-09-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allogeneic bone marrow-derived MSCs | Cell therapy | 1 cells/kg | Intravenous |
| Subject | Allogeneic bone marrow-derived MSCs | Cell therapy | 3 cells/kg | Intravenous |
| Subject | Allogeneic bone marrow-derived MSCs | Cell therapy | 6 cells/kg | Intravenous |
| Subject | Allogeneic bone marrow-derived MSCs | Cell therapy | 10 cells/kg | Intravenous |